Drug Trial Radar · NCT03879772
Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)
Last checked: Nov 20, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
679
Actual
Start
Mar 12, 1996
Primary completion
Jul 1, 1996
Study completion Jul 1, 1996
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to identify the lowest dosage of mometasone furoate nasal spray (MFNS) that provided adequate efficacy with an acceptable safety profile for children (ages 6-11) with seasonal allergic rhinitis (SAR). The MFNS dose levels of 25, 100, and 200 mcg QD were compared with beclomethasone dipropionate (BDP), as an active control, and placebo.
Conditions
- Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate nasal sprayDrug
intranasal administration
Beclomethasone dipropionate nasal sprayDrug
intranasal administration
Placebo nasal sprayDrug
intranasal administration
Chlorpheniramine maleate syrupDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Total Nasal Symptom Score (TNSS) at Day 8 as Assessed by InvestigatorTime frame: Baseline (Day 1) and Day 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.